Product Code: GMDHC07971CDB
Summary
Global Markets Direct's, 'Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc.
- The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Immunomic Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Immunomic Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Immunomic Therapeutics, Inc. Snapshot
- Immunomic Therapeutics, Inc. Overview
- Key Information
- Key Facts
- Immunomic Therapeutics, Inc. - Research and Development Overview
- Immunomic Therapeutics, Inc. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Combination Treatment Modalities
- Pipeline Products - Out-Licensed Products
- Out-Licensed Products/Combination Treatment Modalities
- Immunomic Therapeutics, Inc. - Pipeline Products Glance
- Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- Immunomic Therapeutics, Inc. - Early Stage Pipeline Products
- Preclinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Immunomic Therapeutics, Inc. - Drug Profiles
- TriMix-DC
- Product Description
- Mechanism of Action
- R&D Progress
- anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine
- Product Description
- Mechanism of Action
- R&D Progress
- ASP-4070
- Product Description
- Mechanism of Action
- R&D Progress
- Cellular Immunotherapy for HIV
- Product Description
- Mechanism of Action
- R&D Progress
- Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme
- Product Description
- Mechanism of Action
- R&D Progress
- MC-LAMP-Vax
- Product Description
- Mechanism of Action
- R&D Progress
- pp65 DC + Td
- Product Description
- Mechanism of Action
- R&D Progress
- ARA-LAMP-Vax
- Product Description
- Mechanism of Action
- R&D Progress
- HIV-LAMP-Vax
- Product Description
- Mechanism of Action
- R&D Progress
- TN-LAMP-vax
- Product Description
- Mechanism of Action
- R&D Progress
- Antigen mRNA Vaccine + LAMP
- Product Description
- Mechanism of Action
- R&D Progress
- JCC-LAMP-Vax
- Product Description
- Mechanism of Action
- R&D Progress
- Multi-LAMP-Vax
- Product Description
- Mechanism of Action
- R&D Progress
- Immunomic Therapeutics, Inc. - Pipeline Analysis
- Immunomic Therapeutics, Inc. - Pipeline Products by Target
- Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration
- Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type
- Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action
- Immunomic Therapeutics, Inc. - Recent Pipeline Updates
- Immunomic Therapeutics, Inc. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Immunomic Therapeutics, Inc., Key Information
- Immunomic Therapeutics, Inc., Key Facts
- Immunomic Therapeutics, Inc. - Pipeline by Indication, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016
- Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
- Immunomic Therapeutics, Inc. - Phase II, 2016
- Immunomic Therapeutics, Inc. - Phase I, 2016
- Immunomic Therapeutics, Inc. - Preclinical, 2016
- Immunomic Therapeutics, Inc. - Discovery, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Target, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016
- Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
- Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2016
- Immunomic Therapeutics, Inc., Other Locations
List of Figures
- Immunomic Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016
- Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016
- Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016
